The concept of selective affinity of TMZ towards monocytes was further confirmed in an animal experiment where either GL261 mouse glioma cells in a syngeneic model or U87 human glioma in a xenograft model were treated with systemic application of anti-CCL2 monoclonal antibody (MAb). This evidence concerns the gene CCL2 and central nervous system cancer.